Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.
about
Enteric microbiome metabolites correlate with response to simvastatin treatmentMetabolomics reveals amino acids contribute to variation in response to simvastatin treatmentApplications of metabolomics in cancer researchThe human microbiome: our second genomePharmacometabolomics-aided Pharmacogenomics in Autoimmune DiseaseGut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of MetabolomicsNuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applicationsRole of the normal gut microbiotaMetagenomic surveys of gut microbiotaMicrobiology and ecology are vitally important to premedical curriculaMetabolomics: A Tool Ahead for Understanding Molecular Mechanisms of Drugs and DiseasesA microbiological revolution meets an ancient disease: improving the management of tuberculosis with genomicsDo interactions between gut ecology and environmental chemicals contribute to obesity and diabetes?Epigenetics advancing personalized nanomedicine in cancer therapyThe gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseasesPathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized MedicineThe Impact of the Gut Microbiota on Drug Metabolism and Clinical OutcomeApplying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the futureTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityDeveloping a metagenomic view of xenobiotic metabolismDiversity, stability and resilience of the human gut microbiotaNanoparticle toxicity by the gastrointestinal route: evidence and knowledge gapsSite and strain-specific variation in gut microbiota profiles and metabolism in experimental miceAn effective assessment of simvastatin-induced toxicity with NMR-based metabonomics approachConsensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cellsPrediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serumPharmacometabolomic approach to predict QT prolongation in guinea pigsIdentification of differential responses to an oral glucose tolerance test in healthy adultsTowards structural systems pharmacology to study complex diseases and personalized medicinePrediction of glycated hemoglobin levels at 3 months after metabolic surgery based on the 7-day plasma metabolic profileComparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen ToxicityPredose and Postdose Blood Gene Expression Profiles Identify the Individuals Susceptible to Acetaminophen-Induced Liver Injury in RatsLiquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN databaseMetabolomics enables precision medicine: "A White Paper, Community Perspective"The intestinal microbiome and surgical disease.Breath biomarkers in toxicology.Dominant components of the Thoroughbred metabolome characterised by (1) H-nuclear magnetic resonance spectroscopy: A metabolite atlas of common biofluids.Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Technology and techniques for microbial ecology via DNA sequencing
P2860
Q21135141-9A506DEC-5DCD-4096-9E81-2AD8D8DA8BA1Q21561017-84C1F8F6-C069-4676-933D-1F6DF4673746Q24600728-B94CE747-F895-4A9E-92D1-5BB29576150EQ24601696-25475168-E9BA-4095-BD7B-55FFEBBE3DC4Q26748481-53E05F3F-875C-4D92-B635-89E396AB926DQ26753047-9500DDB2-6C08-45CA-8125-DEA60D509F49Q26772297-BA11DD6A-9242-44E6-BA7E-6D87387A7E9FQ26798294-6F2311D5-D731-4D5E-B830-D16C3C1F1873Q26799820-6651B497-2725-4215-A3CA-CAB541658CC8Q26801329-D5AC85CD-289B-46A7-AB78-D0799FCF05B7Q26827107-71AB52E8-E554-48B5-9E76-D7B53298C35AQ26999868-9C4AC649-A3DE-4D7E-B0AC-6B189474DA6CQ27010006-3D9A0E15-BCAB-4073-B741-9700246CDCC6Q27010637-89426B8C-AE4F-4335-90A5-D3E3EEEF8319Q27021692-DCAC5CFB-AF38-4281-8F72-32F37A426315Q27690772-FC9D19F4-22C6-42AE-8A72-D244835E36C4Q28067029-D2F0F581-BF63-49CC-B50F-B55EF6A42C01Q28071938-61F84D46-10E4-42A9-9864-3157729D4059Q28074451-610CE193-AB4A-4255-B3EB-85DCFA521656Q28087473-EF2D8907-2E4B-4E04-8FEA-4B5606CFD9FBQ28273307-992FA832-983B-4DBF-A6FC-53C9C84478A1Q28274959-C5083BD3-E6F2-474F-9C85-67927C9D6B61Q28390761-0C7B81FC-A28C-4E0D-A7DE-150D971377C4Q28472438-067D2416-724B-4FBB-A5B1-5654F81D60FBQ28477228-F9BBEA02-227E-40B0-9D15-68CDC2CFD97DQ28477581-88526B81-25A1-4282-A1E9-AC7F23213C0DQ28482330-0E3DD369-8BCA-45E7-9AA1-43C8C16C55B1Q28485993-8A815400-1097-46D9-AF56-6F34304ECBFAQ28535572-BF60EF60-B8F7-4053-85E7-D03E7EB8597EQ28538838-BAC50900-4B1D-43DD-BADA-F64476BDAED0Q28544823-F5E5461B-F296-4752-823D-49D97C3098A9Q28546783-F15AE16C-0A5E-45B2-BA77-B34194F5399BQ28550555-65126E89-3EF0-42AF-8F04-AD572B9B4FFFQ28686521-7DBFD562-F783-464C-9E73-A06C050541C9Q28831476-EE2E6458-316E-4B29-ADEE-84A9A824D38EQ30248605-BD4B35DB-F962-4433-86B5-1C86200A89B6Q30392488-F579D1F0-0D93-40A6-B9CE-DFE6B8A7343BQ30843221-48A205BA-849D-4FDD-B941-4F2CB1D205BDQ30885784-3CA96F61-319E-462F-BA33-56DBDB9A9759Q31148287-428F9948-212E-4C5C-8AC9-8C0BED0F01F2
P2860
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@en
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@nl
type
label
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@en
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@nl
prefLabel
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@en
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@nl
P2093
P2860
P356
P1476
Pharmacometabonomic identifica ...... fecting human drug metabolism.
@en
P2093
David Baker
Jeremy R Everett
John C Lindon
T Andrew Clayton
P2860
P304
14728-14733
P356
10.1073/PNAS.0904489106
P407
P577
2009-08-10T00:00:00Z